Cell
Volume 175, Issue 6, 29 November 2018, Pages 1665-1678.e18
Journal home page for Cell

Article
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

https://doi.org/10.1016/j.cell.2018.09.038Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Characterization of the mutational landscape of secondary glioblastoma

  • Clonal and subclonal METex14 promote glioma progression and mark worse prognosis

  • PLB-1001 is a highly selective, efficient, and BBB-permeable MET kinase inhibitor

  • PLB-1001 provides a safe and efficacious therapeutic approach for glioma treatment

Summary

Low-grade gliomas almost invariably progress into secondary glioblastoma (sGBM) with limited therapeutic option and poorly understood mechanism. By studying the mutational landscape of 188 sGBMs, we find significant enrichment of TP53 mutations, somatic hypermutation, MET-exon-14-skipping (METex14), PTPRZ1-MET (ZM) fusions, and MET amplification. Strikingly, METex14 frequently co-occurs with ZM fusion and is present in ∼14% of cases with significantly worse prognosis. Subsequent studies show that METex14 promotes glioma progression by prolonging MET activity. Furthermore, we describe a MET kinase inhibitor, PLB-1001, that demonstrates remarkable potency in selectively inhibiting MET-altered tumor cells in preclinical models. Importantly, this compound also shows blood-brain barrier permeability and is subsequently applied in a phase I clinical trial that enrolls MET-altered chemo-resistant glioma patients. Encouragingly, PLB-1001 achieves partial response in at least two advanced sGBM patients with rarely significant side effects, underscoring the clinical potential for precisely treating gliomas using this therapy.

Keywords

cancer genomics
precision neuro-oncology
secondary glioblastomas
MET tyrosine-kinase inhibitor
PLB-1001
clinical trial
data science

Cited by (0)

14

These authors contributed equally

15

Lead Contact